NCT01939132View on ClinicalTrials.gov

Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis

PHASE4UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

November 30, 2014

Conditions
Psoriatic Arthritis
Interventions
DRUG

Open label H.P. Acthar Gel

Open-label H.P. Acthar Gel 80 units given subcutaneously twice weekly for 12 weeks with 12 week extension.

Trial Locations (1)

48910

RECRUITING

Justus J. Fiechtner, MD, PC, Lansing

Sponsors

Collaborators (1)

Mallinckrodt
All Listed Sponsors
collaborator

Mallinckrodt

INDUSTRY

lead

Fiechtner, Justus J., M.D., P.C.

INDIV

NCT01939132 - Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis | Biotech Hunter | Biotech Hunter